FDA 483 - Mayo Clinic Pharmacy - August 15, 2018
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Mayo Clinic Pharmacy in Rochester, MN, a producer of sterile and non-sterile products, revealed significant deficiencies in aseptic processing and contamination control. Observations included inadequate evaluation of microbial contamination in ISO 5 areas, presence of non-microbial contamination, use of non-sterile disinfectants, and insufficient disinfectant contact times. Additionally, the firm failed to perform endotoxin testing for certain multi-dose sterile products.
ID · 986e873a-a7ee-4bfa-8cd6-e5a9680f8fb6